Viatris Inc vs Wix.Com Ltd — how do they compare? Viatris Inc trades at $17.64 (market cap $20.03B), while Wix.Com Ltd trades at $76.56 (market cap $3.11B). The key difference: Viatris Inc is far larger — about 6.4× Wix.Com Ltd's market cap, and Viatris Inc pays a 2.75% dividend while Wix.Com Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Viatris Inc for 57 Days and Wix.Com Ltd for 62 Days on average.
| VTRS | WIX | |
|---|---|---|
Market Cap | $20.03B | $3.11B |
Volume | 14,109,977 | 809,286 |
Sector | Health | Technology |
52-Week High | $18.27 | $145.54 |
52-Week Low | $9.74 | $40.43 |
Typical Hold Time | 57 Days | 62 Days |
Enterprise Value | $32.15B | $4.19B |
Dividend Yield | 2.75% | — |
Signals from Pluang's Aura AI — not financial advice
Viatris (VTRS) trades at $17.44, down 0.29% on the day, with a bullish technical signal from moving averages and oversold short-term RSI. The company reported three consecutive quarterly earnings beats in 2026, with Q2 EPS of $0.69 beating estimates by 14.8%. Revenue for 2025 was $14.3B, though net income was negative $3.51B, reflecting margin pressure. Positive news includes a new drug approval in Japan and recognition as a top employer.
The outlook is mixed: strong cash flow generation and deleveraging support shareholder returns via dividends and buybacks, but profitability challenges and high debt levels pose risks. Analyst consensus is a 'Buy' with a $22.17 price target, implying 27% upside. Investment appeal hinges on execution of pipeline growth and margin improvement amid competitive and pricing pressures in the generics market.
Wix.com (WIX) trades at $76.56, up 4.92% in the last 24 hours, with technical indicators showing a neutral to bullish bias. Revenue growth is robust, reaching $1.99B in 2025, but profitability is inconsistent, with a net income margin of -8.19% in 2026. Analyst sentiment is positive, with a consensus buy rating and a $77 price target, though recent class action lawsuits add caution.
The outlook for WIX hinges on sustaining revenue growth while improving profitability. Risks include legal challenges and volatile earnings, but strong analyst support and a solid market position offer potential upside if execution improves.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →